Objective: To determine whether low levels of S100B in serum can predict normal computed tomography (CT) findings after minor head injury (MHI) in adults. Participants: Not applicable. Design: Systematic evidence-based review of the peer-reviewed literature with meta-analytical interpretation. Primary Measures: Not applicable. Results: We identified 12 eligible articles that specifically studied adult MHI patients with S100B and cranial CT scans in the acute phase after injury, comprising a total of 2466 separate patients. Individual negative predictive values of 90% to 100% were found for the ability of a negative (under cutoff) S100B level to predict a normal CT scan. A total of 6 patients included in the studies had low S100B levels and positive CT scans (0.26%) and only 1 of these patients (0.04%) had a clinically relevant CT finding. The pooled negative predictive value for all studies was more than 99% (95% CI 98%-100%), with an average prevalence for any CT finding at 8%. The studies are consistently classed as level 2 and level 3 grades of evidence, suggesting a grade B recommendation. Conclusion: Low serum S100B levels accurately predict normal CT findings after MHI in adults. S100B sampling should be considered in MHI patients with no focal neurological deficit, an absence of significant extracerebral injury, should be taken within 3 hours of injury, and the cutoff for omitting CT set at less than 0.10 μg/L. Care givers should also be aware of other clinical factors predictive of intracranial complications after MHI. Keywords: evidence, guidelines, head injury, management, meta-analysis, MHI, mild, minor, TBI, S100/S-100/S100B T RAUMATIC HEAD INJURY is a significant cause of mortality and morbidity in adults 1 and is the leading cause of death in childhood.
T RAUMATIC HEAD INJURY is a significant cause of mortality and morbidity in adults 1 and is the leading cause of death in childhood. 2 Minor head injury (MHI) represents up to 95% of head injuries 3 and management today involves computed tomography (CT) or in-hospital observation, although neither of these options are ideal. In-hospital observation is not costeffective 4, 5 and CT is sometimes impractical, not always available, involves potentially harmful ionizing radiation, and is also relatively costly. 6, 7 Furthermore, only a small proportion of patients with MHI have intracranial injuries (ICI) and even fewer require neurosurgical
Can Low Serum Levels of S100B Predict Normal CT Findings?
229 presence and severity of neurological disorders. S100B was originally thought to be specific to astroglia in the central nervous system, but further studies have shown the protein in neurons 17 and in extracerebral tissues such as adipocytes, chondrocytes, lymphocytes, and bone marrow cells. 18 The biological function of S100B is still somewhat unclear, but it seems to have both toxic/degenerative and trophic/reparative roles depending on the concentration of the protein.
19 S100B is found in low, but measurable, levels in healthy individuals, rises rapidly in blood after head injury and has a short half-life of about 30 to 90 minutes. 20, 21 The possibility of using serum S100B in patients with MHI was first reported in 1995. 22 It was first thought that S100B release was a biomarker of subtle brain damage after MHI, although data suggest that an equally relevant mechanism may involve the release of extracellular S100B through a disrupted blood-brain barrier, without necessarily involving actual cellular damage. 19, 23, 24 Since the original studies from the mid-1990s, several studies from different research groups have explored the ability of this biomarker to aid in decision making in the initial phases of MHI management. These efforts concentrate on the high sensitivity of S100B for CT-evident injury, rather than specificity, as several studies have shown clear extracerebral sources of the protein. 25, 26 This report will summarize and analyze the evidence currently available to attempt to answer the following key clinical question: Can low serum levels of S100B predict normal CT findings after minor head injury in adults?
METHODS

Definition of minor head injury
There exist several different definitions of MHI, but all have the common goal to classify patients according to the risk of developing acute intracranial complications, such as intracranial hemorrhage and brain contusions. Most definitions of MHI include a short period of unconsciousness or amnesia and grading according to Glasgow Coma Scale (GCS). In 1995, Stein and Spettell presented their definition based on 25 000 patients where patients with MHI are graded as GCS 14 to 15. 27 Patients with a GCS score of 13 are sometimes included in the MHI group despite the increased incidence of intracranial lesions in this group. 28 In contrast, including only patients with a GCS score of 15 results in a patient group with a very low risk of clinically important complications. 29 Mild traumatic brain injury (mTBI) is a term also used in the literature, essentially referring to an injury to the brain itself, rather than the process and presentation of the injury. This definition is, however, problematic in the sense that it implies a diagnosis of brain injury without the actual diagnostic process being completed. Without elaborating further on nomenclature issues, MHI will be defined as follows for the purpose of this review: History of nonpenetrating head injury, GCS score 13 to 15 at admission, loss of consciousness (LOC) or amnesia. This wide definition includes typical aspects from different MHI and mTBI definitions while still focusing on the process and presentation of the head trauma, rather than the final diagnosis after neuroradiology or hospital stay. Studies of patients presenting with GCS scores of 12 or less were not included in the analysis.
Index test
The analysis of S100B in serum has been achieved through several different techniques, including immunoradiometric assays, immunoluminometric assays, enzyme-linked immunosorbent assays, and electrochemiluminescence immunoassays. These are available from several commercial sources and differ in performance. 19 For the purpose of simplicity in this report, no distinction will be made between different assays despite the fact that discrepancies in analytical performance may be of importance.
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Reference test
CT is not 100% sensitive for intracranial complications after MHI. [31] [32] [33] However, cranial CT is widely accepted as the gold standard in detection of intracranial lesions after MHI and evidence shows that patients with a normal CT scan after MHI have a minimal risk of developing an intracranial lesion. 8 Cranial CT will therefore be considered as the reference test in this report.
Search strategy and identification of relevant studies
To adequately answer the key question, we performed a Medline search for studies between 1983 (when CT became clinically available) to the present day using appropriate combinations of MeSH terms and key words; head injury, TBI, mTBI, MHI, minor, mild, minimal, serum, biomarkers, S-100, S100, S-100B, S100B, S-100BB, S100BB, computed tomography, CT, CCT, and management. A less comprehensive TripDataBase and Clinical Queries search using these keywords was also conducted. We performed this relatively wide search to include the maximum number of relevant patients. The search was complemented by examining the bibliographies of identified relevant studies.
Data extraction
The eligible studies were examined and relevant data recorded including; first author, year of publication, study design, patient group and inclusion criteria, characteristics of the index test including cutoff used, relevant results with respect to the key question including predictive statistics, and study limitations. If certain key factors or data were missing from the studies, authors were contacted for clarification. In the case of multiple studies from the same research group, authors were also contacted to ensure unique patients. Because a cutoff of 0.10 μg/L has independently been reported from different research groups, 21 ,34 results in relation to this level were extracted, if possible, to attempt an interpretation of data using the same cutoff.
Quality assessment
Studies were graded and assigned a quality rating with respect to the key question according to the Centre of Evidence Based Medicine (CEBM) criteria. 35 Studies were graded from 1 (strongest evidence, for instance reports of clinical decision rules and high quality validating study) to level 5 (weakest evidence, often expert opinion). Following this, the 14 Quality Assessment of Diagnostic Accuracy Studies (QUADAS) criteria 36 were applied. Studies receive scores from 1 (lowest quality) to 14 (highest quality) based on 14 separate criteria relevant to diagnostic studies accounting for bias (items 3-7, 10-12), variability (items 1-2), and reporting (items 8-9, 13); 1 point was given for each criteria satisfied. Studies with 3 or more missing points (ie, 11 points or less in total) were downgraded one level. Studies therefore received a final evidence level accounting for both criteria. This approach was used to account for classical features of studies (CEBM) including specific details related to diagnostic studies (QUADAS). The final recommendation (A to D) is based on CEBM criteria; grade A referring to consistent class 1 studies, grade B for consistent level 2 or 3 studies (or extrapolations from level 1 studies), grade C for level 4 studies (or extrapolations from level 2 or 3 studies), and grade D for level 5 studies.
Data presentation and analysis
Studies are briefly presented in evidentiary tables. Data are presented in table form with corresponding number of patients with true positives (TPs), false positives (FPs), false negatives (FNs), and true negatives (TNs) for each study along with relevant comments concerning FN patients. We explored heterogeneity using a using a Chi-squared test. Because of heterogeneity, weighted pooled sensitivity and specificity were calculated with a random effects model. We calculated likelihood ratios and predictive values from the pooled sensitivities and specificities derived from the random effects model. This approach also eliminates differences in prevalence from the studies and allows for calculation of predictive values corresponding to typical prevalence levels for this patient group.
RESULTS
A total of 272 abstracts were examined independently by the authors and 49 full manuscripts were chosen and studied in detail. Twelve studies were found eligible for the current review and data analysis, 21, 34, [37] [38] [39] [40] [41] [42] [43] [44] [45] [46] consisting of 2466 separate patients. These studies are presented in the evidentiary table, Table 1 . The number of patients included in the cohorts range from 50 to 1309 patients (average 206 patients). Time from injury to S100B sampling ranged from less than 3 hours to less than 24 hours according to inclusion criteria (with all but one study sampling patients within 12 hours). The settings for all studies were emergency departments in the following countries; Sweden, Norway, Germany, France, Slovenia, Brazil, and the United States. In 6 of the studies, data concerning a cutoff of 0.10μg/L could be analyzed, in some instances after contact with authors. Table 2 presents studies with accompanying TP, FP, FN, and TN results, also including pathological radiological data from patients with S100B under the cutoff level.
The 12 eligible studies show similar results with high individual sensitivities (75%-100%). More importantly, they show very high individual NPVs (90%-100%) for the ability of a negative (under cutoff level) S100B level to predict a normal CT scan. Six FNs (low S100B, but positive CT scans) were found in the total patient group of 2264 patients (0.26%). These diagnoses were 2 small traumatic subarachnoid hemorrhages, 2 skull fractures, 1 patient with a small cerebral contusion, and 1 patient with an acute subdural hematoma. Only the latter patient needed surgical intervention (1 patient from the total of 2264, 0.04%), 17 days after the trauma, from neurological deterioration.
Meta-analysis
Sensitivities were only borderline homogenous (Q = 19, degrees of freedom = 11, P = 0.054) but specificities were clearly heterogeneous (Q = 168, P < .001). Considering only those studies in which a cutoff of 0.10 μg/L could be evaluated did not eliminate heterogeneity (Q = 15, degrees of freedom 7, P = .042 for sensitivity and Q = 27, degrees of freedom 7, P < .001 for specificity). Because of this heterogeneity, a random effects model Abbreviations: CT, computed tomography; GCS, Glasgow Coma Scale; tSAH, traumatic subarachnoid hemorrhage; SDH, subdural hematoma.
was utilized. Figures 1 and 2 show graphical presentations of sensitivities and specificities from the studies, and Figure 3 shows a summary receiver operating characteristic curve based on the same data. Table 3 presents the weighted pooled statistical data from the 12 studies. The pooled sensitivity for all studies was 97% (95% CI 91%-99%) and the pooled specificity 40% (95% CI 30%-51%). Considering the 6 studies where a cutoff of 0.10 μg/L could be evaluated, sensitivities and specificities were 96% (95% CI 85%-99%) and 30% (95% CI 23%-38%), respectively. The prevalence of intracranial findings after MHI has been reported to be in the ranges of 1% to10%. 8, 9 Corresponding NPVs for prevalence levels of 1%, 5%, 10%, and 20% are 100% (95% CI 100%-100%), 100% (95% CI 99%-100%), 99% (95% CI 97%-100%), and 98% (95% CI 94%-99%), respectively. PPVs considering prevalence levels of 1%, 5%, 10%, and 20% are 2% (95% CI 1%-2%), 8% (95% CI 7%-9%), 15% (95% CI 13%-18%), and 29% (95% CI 25%-33%), respectively. The average prevalence from the included studies in this article was 8%, giving a NPV of more than 99% (95% CI 98%-100%).
The studies are consistently classed as level 2 and level 3 grades of evidence, which suggests a grade B recommendation according the CEBM criteria.
DISCUSSION
Limitations
The included studies use different assays for detection of S100B in serum, which is a potential source of error. Different assays may report different levels of S100B from the same sample from differences in performance characteristics. 30 Four studies used the LIAI-SON assay from Sangtec (total number of patients 555), 2 used the Elecsys assay from Roche (total number of patients 1359), 2 used immunoluminometric assays from Sangtec (total number of patients 118), 1 used immunoradiometric assays from Sangtec (total number of patients 50), and the final study used a Sangtec 100 (total number of patients 182). Hence, the Elecsys assay accounts for 60% of the patients and the LIAISON accounts for 25%. Because the LIAISON assay reports higher values of S100B than the Elecsys assay, 30 it is unlikely that the pooled sensitivity would be decreased if differences in assay performance were corrected. Ultimately, it is most correct to apply evidence from a certain assay to only those patients measured with the same assay. This approach is unpractical however, because dif- ferent assays will always exist and new assays with new technologies will replace older versions. This problem is therefore not unique to S100B and difficult to account for.
Because S100B is also produced by melanocytes, different races could have different basal levels of S100B. This aspect has not been examined in these studies and should be considered in future studies.
According to the QUADAS tool, the included patients are judged relatively representative for the target population for the test. Despite this, the prevalence of intracranial complication differs between the studies, generally being higher than values reported in the literature. 8, 9 In particular, 2 of the studies had a prevalence of CT findings over 20%, yet both these also showed NPVs of 100%. 41, 42 These aspects, together with the observed heterogeneity, are worrying and suggest bias but cannot be penetrated further in this report. However, consideration for this was achieved through 
Detection of CT findings versus surgical intervention
Studies concerning the early diagnostic management of head injury usually report both CT findings and neurosurgical intervention (alternatively clinically important brain injury) as endpoints. [9] [10] [11] 13 In this report, we focus only on CT findings. However, it is obvious, without statistical analysis, that the sensitivity of S100B for surgical intervention (or clinically important brain injury) would be even higher because only 1 patient (subdural hematoma) would be included in this group. Because the prevalence of surgical intervention and clinically important brain injury is very low after MHI (0.1%-1%), 8, 9 the NPV based on the data would be 100% with very narrow CIs.
Can S100B be used in other severities of head injury?
The predictive performance of S100B will depend on which patients are considered for testing. This is related to the pretest probability (prevalence) of the relevant outcome; in this case, CT findings or clinically relevant intracranial complication. A lower pretest probability will result in an increased NPV and a decreased PPV and vice versa. This also stresses that S100B can initially be applied only to similar patient cohorts as those reported in the studies examined within this report. Applying S100B to other patients will result in different posttest probabilities, which may cause a diagnostic imbalance toward false negatives (missed patients) or false positives (unnecessary CT scans). Oh et al found a sensitivity of 97%, a specificity of 54%, an NPV of 88%, and a PPV of 84% for CT or magnetic resonance imaging findings using a cutoff of 0.105 μg/L in a cohort of 45 patients with mild, moderate, and severe head injury. 47 In fact, only 1 patient with radiological findings showed a S100B below the reference limit, despite the high prevalence of complications and the use of MRI as the reference test.
The emergence of new decision rules for CT scanning has further complicated this issue. Ideally, S100B could be used in conjunction with these rules. Because of the very high sensitivity of S100B, the test should be made before applying the decision rule when the pretest probability is low. Applying S100B to patients selected for CT (via the decision rule) would lead to a lower negative prediction because of a higher pretest probability. It must be remembered that, in contrast to the clinical decision rules, S100B is an objective measurement and is not affected by intoxication in MHI. Studies of CT prediction combining S100B with recently presented clinical decision rules are welcomed.
Is S100B influenced by alcohol intoxication?
Clinical parameters included in existing and proposed management guidelines may be difficult to interpret in intoxicated patients, and some of these guidelines include intoxication as a indicator for CT scanning. 9, 48 In addition, CT scanning or hospital observation may be practically difficult in these patients. Because between 30% and 50% of patients with MHI are intoxicated, 49, 50 this presents a practical management problem. Small elevations of S100B after moderate alcohol intake in nonhead-injured subjects has been reported, 51 although S100B does not seem to be affected by alcohol intoxication in head-injured patients. 40, 51, 52 This is confirmed by unpublished data from our clinic where intoxicated patients show similar levels of S100B compared with sober patients.
What is the evidence for S100B use in children with head injury?
The management of children with traumatic head injury is more complicated than in adults, because patient history may be unreliable and physical examination can be practically difficult. Also, CT scans of children should be minimized because of potential health risks. 7 Despite recent impressive reports of prediction rules, 53 a biomarker is welcomed in this patient category. Reference levels for healthy children are higher than in adults. [54] [55] [56] Berger and colleagues have published several studies concerning S100B levels in children after TBI, [57] [58] [59] [60] showing promising results. These studies also highlight the diagnostic problem of inflicted TBI, an area where a reliable biomarker may have considerable clinical impact. Bechtel et al 61 recently reported a study with S100B levels in serum after closed head injury in children younger than 18 years. They found that S100B was a poor predictor of intracranial injury at a cutoff of 0.5 μg/L with a PPV of only 20%, but found a high NPV of 90% at the same cutoff. They also investigated the impact of bone fractures on S100B levels and, similar to results in adult studies, 25 found that these extracranial injuries may be responsible for the poor specificity of S100B in trauma. Castellani et al present a study of 109 children with MHI in which they found a sensitivity and NPV of 100%, a specificity of 42%, and a PPV of 46% for CT findings using a cutoff of 0.16 μg/L derived from analysis of healthy children. 62 Venous cannulation is not always performed after MHI in children, especially in asymptomatic cases. Reports considering urine measurements of S100B in children showed initial promise. 63, 64 However, in a casecontrol pilot study, Pickering et al concluded that early (<12 hours after injury) urinary levels of S100B are not useful in pediatric head injury. 65 A recent study by Schultke et al confirmed these findings. 66 Measurements of capillary S100B would be a suitable option because this sampling method is often used for children in the emergency department. Unpublished results from an ongoing study in Sweden show that capillary S100B is significantly correlated to, but not interchangeable with, venous samples. Therefore, separate reference and injury values must be studied before this method can be considered. Summarizing, although reports are generally promising, the evidence for S100B in pediatric TBI is insufficient and must be expanded before it can be considered for clinical utility.
What is the evidence for other biomarkers in MHI management?
Because S100B is not specific to the brain, other more specific biomarkers are needed to obtain a clinically useful specificity and PPV for brain injury after MHI. Several other biomarkers have been studied in head injury, including glial fibrillary acidic protein, [67] [68] [69] brain-and heart-fatty acid-binding proteins, 70 myelin basic protein, 71 neuron-specific enolase, 72 and alpha IIspectrin breakdown products. 73 Of these, glial fibrillary acidic protein seems most interesting with a much better clinical specificity than S100B. 74 However, these markers have not been sufficiently investigated in MHI and further studies are needed before any conclusions can be made.
Will S100B miss important CT complications?
Comparison with other clinical tests S100B used in the proposed setting is not 100% sensitive. It is unreasonable to expect an actual 100% sensitivity or NPV from a diagnostic test. In this clinical situation, a very high sensitivity and even higher NPV is acceptable if combined with other diagnostic variables. It is important that clinicians are aware that neither decision rules nor recommendations are completely reliable but merely based on the best available evidence. 75 If S100B was to be used alone as a diagnostic tool after MHI, without considering other clinical aspects, this will eventually lead to a false negative result (ie, a case of ICI after MHI will be missed). Parallels can be made with other diagnostic tests in potentially serious clinical conditions.
Pulmonary embolism (PE) is a feared clinical condition with relatively high morbidity and mortality. Diagnostic problems with PE show several parallels with intracranial complications after MHI. The blood test D-dimer has been used for many years for the purpose of selecting patients who do not need radiological investigation. Despite many years of experience with the test and multiple efforts of refining assays and guidelines, the sensitivity and NPV of D-dimer for PE has recently been reported to be 95% (95% CI, 73.1%-99.7%) and 99% (95% CI, 96.2%-99.9%), respectively, with low specificity and PPV. 76 This is inferior to the performance of S100B. The performance of D-dimer is even poorer when referring to deep vein thrombosis instead of PE with sensitivities/NPVs of 88%/99%, 90%/96%, and 92%/84% in low-, moderate-, and high-prevalence groups, respectively. 77 Myoglobin, troponin I, and troponin T have largely replaced the rather unspecific creatine kinase MB as a heart-specific biomarker used in the diagnostics of acute myocardial infarction. In a recent large multicenter study, Keller et al found sensitivities/NPVs for acute myocardial infarction of 61%/87% for myoglobin, 91%/96% for troponin , and 73%/91% for troponin T. 78 Epidural hematoma is a feared complication to MHI. Initially, before clinical manifestation, this condition may not be associated with any actual brain damage, but is rather an expanding extradural mass with a risk of future brain damage if left untreated. Hence, a biomarker of brain damage may be insensitive of this condition. However, all epidural hematomas reported in the literature have shown S100B levels over 0.10 μg/L, although the values are often relatively low, 34, 79 which supports the idea that S100B is also a biomarker of blood-brain barrier disruption 23, 24 as well as a marker of actual cell damage. Six patients from this report had pathological CT findings and a S100B level below cutoff. Only 1 of these patients required surgical treatment and would be classified as clinically important brain injury according to the Canadian CT Head Rule decision rule. 10 This patient (an 83-year-old female with cardiopulmonary disease) had an admission GCS score of 15 with risk factors of headache and vomiting and would therefore be missed by several of the existing clinical guidelines. Also, this patient was first surgically treated after 17 days posttrauma for neurological deterioration (presumably then a chronic subdural hematoma and hence likely to be eventually detected by clinical means). 45 The half-life of S100B has been shown to be as short as 25 minutes, 20 although a recent study in patients with MHI has shown a half-life of 97 minutes. 80 This implies that the timing of S100B sampling is important to avoid missing patients with CT pathologies. If considered for clinical use, S100B should therefore be taken within 3 hours of injury until more data are available.
Certain clinical risk factors have shown strong associations with intracranial injury. In our opinion, patients with special risk factors, particularly clinical signs of skull fracture, posttraumatic seizures, certain anticoagulation therapies, and shunt-treated hydrocephalus should not undergo S100B sampling, but should receive a CT according to normal practice, 12 because these factors have not been properly addressed in the literature. 
Future aspects
Serum S100B levels show a high sensitivity and NPV for intracranial complications after MHI. The specificity is poor, mostly from contamination of extracerebral S100B, 25 although it is also possible that S100B may be more sensitive for certain trauma-induced lesions than CT 81 and elevated levels may, in some cases, be reflecting subtle brain damage. It is also possible that extracranial trauma may release cytokines that can disrupt the blood-brain barrier and allow extracellular cerebral S100B to enter the bloodstream. The development and validation of other, more specific brain biomarkers, should address these aspects. Specificity issues aside, this objective biochemical tool may reduce the frequency of CT scanning after MHI by as much as 30%. Incorporating methods of correction to account for extracerebral contamination may further improve this figure. 44 These are, however, only theoretical values of CT reduction and the health economics of S100B implementation remain to be elucidated. An interesting report from Ruan et al addresses this aspect and the authors conclude that S100B can be cost saving, depending on the clinical utility and setting. 82 Preliminary data from an ongoing study in a level III trauma hospital in Halmstad, Sweden, indicate that S100B has reduced CT scans after MHI by approximately 15% and is cost effective. During 3 years of clinical application, no patients have been missed by S100B, currently used as a clinical decision rule in conjunction with the Scandinavian Neurotrauma Committee guidelines. Several studies concerning the use of brain biomarkers, including S100B, in pediatric head injury are underway.
Serum levels of S100B are used in MHI management in several European countries, including Sweden and Germany, in conjunction with existing guidelines, although none of these has been published or validated.
CONCLUSION
Low serum S100B levels accurately predict normal CT findings after MHI in adults. The evidence in this report supports a grade B recommendation. S100B sampling should be considered in MHI patients with no focal neurological deficit, an absence of significant extracerebral injury, should be taken within 3 hours of injury and the cutoff for omitting CT set at less than 0.10 μg/L. Approximately one third of CT scans may be omitted using this approach in the defined patient group, although care givers should be aware of other clinical factors predictive of intracranial complications after MHI.
